Ranibizumab for the treatment of Age-Related Macular Degeneration related research hotspot and dynamic

Abstract Objective: Bibliometric analysis in the research area of Ranibizumab and Age-Related Macular Degeneration(AMD) was conducted to describe the current trends in international research dynamics in the field and to present a visual representation of the research hotspots and difficulties in ophthalmic drugs in the last fifteen years. Method: In this cross-sectional study, bibliometrics analyzed data retrieved and extracted from the Web using the Science Core Collection (WOSCC) database to analyze the evolution and thematic trends in the delivery of studies from January 1, 2008, to September 2, 2023, for Ranibizumab and AMD studies. A total of 2691 articles on the field were assessed for specific characteristics such as year of publication, journal, author, institution, country/region, citation and keywords. Co-authorship analysis, co-occurrence analysis, co-citation analysis, and network visualization were constructed using VOSviewer. Bibliometrics identified a number of important sub-themes for further discussion and review of characterization. Results: From 2008 to 2023, the cumulative number of articles published globally increased from 1 to 2,691, with the highest number of articles published in 2020 (255 papers). RETINA THE JOURNAL OF RETINAL AND VITREOUS DISEASES published the most manuscripts (285 papers) and was cited (6,496 citations), followed by OPHTHALMOLOGY (193 papers) and GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (163 papers). OPHTHALMOLOGY was the most cited (20,865 citations), with the United States (786 papers, 38,014 citations), univ sydney (98 papers, 5,245 citations), and kim, jong woo (56 papers, 550 citations) being the most productive and influential institutions, countries, and authors, respectively.Co-occurring clusters: the top 100 keywords analyzed form 5 clusters:Marking the emerging frontiers in the field of ranibizumab and AMD. Further discussion of the 5 clusters of research is to assist the researcher in determining the scope of the research topic and planning the direction of the research. Conclusion: The number of publications and citations of research related to Ranibizumab and AMD has been increasing over the last two decades in many countries, institutions and authors. This study reveals the current trends, global collaboration patterns, basic knowledge, research hotspots and developmental trends in Ranibizumab associated with AMD research. New solutions of Ranibizumab for AMD such as shorter number of injections, prolonged drug efficacy and safety have been the major themes in the last 15 years.